newsmetry
rusign inget started
macro

Immunocore: nine-month KIMMTRAK sales rise to $324.8M, but Q3 revenue slips

Immunocore reported via GlobeNewswire that nine-month KIMMTRAK sales reached $324.8M, while Q3 sales fell to $102.2M and the net loss widened.

published on Newsmetry
original source published

the same feed is available to bots and dashboards through the api. connect the api →

Newsmetry newsroom

what happened

Immunocore Holdings plc (IMCR) said KIMMTRAK net sales were $102.2M in the third quarter of 2026, compared with $103.7M a year earlier. Over nine months, sales came to $324.8M, up from $295.5M. The figures were published by GlobeNewswire.

The third-quarter net loss grew to $14.2M from $0.2M, and research and development spending rose to $74.7M from $70.6M. The company attributes the quarterly sales decline to wholesaler stocking in the second quarter of 2026 and one extra U.S. sales week in the third quarter of 2025.

Cash and securities increased to $901.3M from $864.2M. The company, however, expects to pay about $120M in sales-related rebates in the fourth quarter of 2026. Enrollment in the TEBE-AM study is complete with 540 patients, and topline overall survival data are expected in the second quarter of 2027.

why it matters

The key question for the market is the gap between stronger nine-month sales and a weaker quarterly result. Rebate payments in the fourth quarter will reduce the cash position, so the next major reference point remains the TEBE-AM data expected in the second quarter of 2027.

market impact

IMCR: nine-month sales growth supports the stock, while the wider loss and rebate payments weigh on it

  • Immunocore shares (IMCR) mixed — nine-month sales growth is offset by a wider quarterly loss and rebate payments

tags

EarningsStockUnited States

instruments

IMCRImmunocore Holdings plc

sources

  1. Immunocore Holdings plc (IMCR) Reports $324.8M in Nine-Month KIMMTRAK Sales — globenewswire.com, 6 November 2026 at 14:00 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗

related stories